Voluntary Recall Information

Philips Respironics Sleep and Respiratory Care devices

Information for patients


Patient safety is our top priority. We are committed to completing the remediation for all affected patients to make sure you receive safe and effective therapy. 


We know that each situation is unique depending on your affected device and personal situation. If you have questions about the remediation process or need any additional support once you have received your replacement device, please visit our updated Contact and Support page.


We have devices available to ship, and we are actively encouraging patients who have registered their device to visit the Patient Portal in case further action is needed before we can ship your replacement device / complete your remediation pathway.


If you registered an affected device and are still waiting for your replacement, it is likely because we need important information or consent from you. Without this information, we are unable to ship your replacement device. Depending on your affected registered device, you may have alternative options.  

Stop icon

Ozone and UV light cleaning products are not currently approved cleaning methods for sleep apnea devices or masks and should not be used.

Latest updates

A conversation with David Ferguson, Business Leader, Sleep and Respiratory Care

David Ferguson, Business Leader, Sleep & Respiratory Care
We have devices ready for patients, and we are making every effort to ensure they get into the hands of those who are waiting for them.”

David Ferguson

David Ferguson, Business Leader, Sleep & Respiratory Care, joined Philips in March 2021. Since then, he has led the organization through the voluntary medical device recall of certain CPAP, BiPAP and Mechanical Ventilator devices. With the comprehensive test and research program for affected CPAP/BiPAP sleep therapy devices now complete, we asked him about what’s changed since the start of the recall, what the test results mean for patients, and what to expect from Philips Respironics in the future.

† First-generation DreamStation, System One and DreamStation Go devices

July 2023 latest results and conclusions for sleep therapy devices related to the impact of ozone cleaning shows no appreciable harm to health in patients


Philips Respironics completed the analyses for System One and DreamStation Go sleep therapy devices indicating that the volatile organic compounds (VOCs) and the particulate matter (PM) emissions related to foam degradation are within the appliable safety limits. Additional visual assessments have been performed and confirm the low prevalence of significant foam degradation.

Resolution of US economic loss litigation reached


Philips has reached an agreement, subject to Court approval, to resolve all economic loss claims brought by private plaintiffs in the United States related to the Philips Respironics voluntary recall of certain sleep and respiratory care devices.

Patients, hospitals and sleep labs eligible for benefits under the agreement do not need to take any action at this time in order to participate in the proposed settlement. The settlement must be approved by the Court, and additional information will be provided to you in the future.

All related inquiries should be directed to the third-party Settlement Administrator, Angeion Group. For more information, please visit www.RespironicsCPAP-ELSettlement.com or call 855-912-3432.

You are about to visit a Philips global content page


You are about to visit a Philips global content page


Our site can best be viewed with the latest version of Microsoft Edge, Google Chrome or Firefox.